生物制品板块1月20日跌0.63%，欧林生物领跌，主力资金净流出3.35亿元

Market Overview - The biopharmaceutical sector experienced a decline of 0.63% on January 20, with Olin Bio leading the drop [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Tonghua Dongbao (600867) with a closing price of 8.81, up 2.20% on a trading volume of 319,000 shares and a turnover of 280 million yuan [1] - Wufan Bio (301393) closed at 55.20, up 1.81% with a trading volume of 22,900 shares and a turnover of 128 million yuan [1] - Kanghua Bio (300841) closed at 76.45, up 1.58% with a trading volume of 23,800 shares and a turnover of 183 million yuan [1] - Major decliners included: - Olin Bio (616889) closed at 25.98, down 3.88% with a trading volume of 87,000 shares and a turnover of 226 million yuan [2] - Junshi Bio (688180) closed at 35.29, down 3.42% with a trading volume of 119,400 shares and a turnover of 425 million yuan [2] - Ganli Pharma (603087) closed at 70.23, down 2.70% with a trading volume of 81,800 shares and a turnover of 577 million yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 335 million yuan from institutional investors, while retail investors experienced a net inflow of 128 million yuan [2] - The capital flow for specific stocks indicated: - Wanze Co. (000534) had a net inflow of 103 million yuan from institutional investors [3] - Watson Bio (300142) saw a net inflow of 40 million yuan from institutional investors [3] - Olin Bio (688319) had a net inflow of 17.96 million yuan from institutional investors [3]